Milestones & Recognitions
Milestones
2024
Sun pharma included in S&P global sustainability notebook
2023
We acquired Concert Pharmaceuticals in USA
2022
We acquired Uractiv portfolio from Fiterman Pharma in Romania
2021
We launched ILUMYA™ (tildrakizumab injection), a treatment for adults living with moderate-to-severe plaque psoriasis in Canada
We launched a speciality dermatology product, WINLEVI® (clascoterone) cream 1% in the U.S. for topical treatment of Acne Vulgaris
We forayed into the nutrition bar segment in India with the launch of Revital NXT, India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
2020
We completed 25 years of making our debut on the Indian Stock Exchanges
We launched ILUMYA™ for treatment of plaque psoriasis in Japan
2019
We acquired Pola Pharma in Japan to strengthen our global dermatology presence
We launched our specialty product, Cequa in the United States for the treatment of dry eyes
We entered Greater China market through partnership with China Medical System Holdings
2018
We launched specialty product, ILUMYA™ (tildrakizumab-asmn) in the United States for treatment of moderate-to-severe plaque psoriasis
2017
We launched specialty product, Odomzo in USA
2016
We acquired 14 brands from Novartis in Japan
We acquired Ocular Technologies, Sarl to strengthen our branded ophthalmic portfolio
We acquired Biosintez to enhance our presence in Russian market
We launched our first branded ophthalmic product, BromSite™ in USA
2015
We acquired GSK’s Opiates business in Australia
We acquired InSite Vision Inc. to strengthen our branded ophthalmic portfolio in USA
2014
We acquired Ranbaxy in a US$ 4 billion landmark transaction to create the world’s 5th largest specialty generic pharmaceutical company
Sun Pharma and Merck & Co. Inc. entered into licensing agreement for Tildrakizumab (MK- 3222)
We acquired Pharmalucence in USA
2012
We acquired Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals in USA
2010
We acquired controlling stake in Israel-based Taro Pharmaceuticals, headquartered in USA to effectively double company’s US business
2008
We acquired Chattem Chemicals Inc, USA
2007
We demerged Sun Pharma Advanced Research Company (SPARC) into a separate entity
2005
We completed buyout of manufacturing unit in Bryan, Ohio, USA
We acquired ICN’s business in Hungary from Valeant Pharma
2004
We set up a new formulation unit in Jammu, India
We commissioned the first joint venture manufacturing unit in Dhaka, Bangladesh
We acquired Phlox Pharma (India) and niche brands from Women’s First Healthcare (USA)
2001
We commenced production at our new formulations unit in Dadra, India
2000
We acquired Pradeep Drug Company in India
1999
We acquired Milmet Labs, Cephalexin and 7ADCA actives manufacturing site in India
1998
We began operations at a new formulation unit in Silvassa, Gujarat, India
1997
We purchased equity stakes in TDPL and MJ Pharma
We had our first international acquisition – Caraco Pharmaceutical Laboratories, USA (completed 100% acquisition in 2010)
We established new research facility in Mumbai, India
1996
We expanded our sales network across 24 countries
We acquired API plant from Knoll Pharma at Ahmednagar, Maharashtra, India
1995
We began production at API manufacturing plant in Panoli, Gujarat, India
1994
We launched Initial Public Offering (IPO)
1991
We established our first research center to create a base for strong product and process development
1988
We launched Monotrate and Angize, our first cardiology productsBoa
1983
Sun Pharma established with five psychiatry products and a two-person marketing team
Sun Pharma set up our first manufacturing facility for tablets and capsules at Vapi, Gujarat, India
Recognitions
2023
We got Great Place to Work Certified
2022
We got Great Place to Work Certified
2022
We were recognised as the #1 generic pharmaceutical company by patient groups in the annual PatientView ‘Corporate Reputation of Pharma’ survey 2021
2021
We received the Golden Peacock Award for Corporate Social Responsibility, 2020
We won the Dun & Bradstreet India Corporate Award under the Sectoral Performance-based category- Pharmaceuticals
We bagged the DIANA (Distribution Industry Award for Notable Achievements in Healthcare) award for ‘Best New Product Introduction/Promotion’ at the Annual Healthcare Distribution Alliance Conference 2021
We were recognized as the Best Innovative Company of the Year 2021 at Indo-American Corporate Excellence Awards.
2020
We were listed among the Forbes World’s Best Employers 2020
Volini, one of our star OTC products was named in Nielsen BASES Top Breakthrough Innovation Winners India 2020 list
We ranked No. 1 in pharma sector and No. 16 overall in the BW Businessworld list of India’s Most Respected Companies
2019
We were listed among the Forbes World’s Best Regarded companies
Our CSR subsidiary, Foundation for Disease Elimination and Control of India was conferred with Mahatma Award for Social Good 2019
Our Mobile Healthcare Unit project was recognised as the Best Public Health Initiative by ACEF Asian Leadership Forum
2018
We were listed among the Forbes World’s Most Innovative companies
We were listed among the Forbes World’s Best Employers
We received Outstanding Contribution in CSR recognition from the Federation of Gujarat Industries
We received Best CSR Practices Award from The Economic Times
Dilip Shanghvi received Lifetime Outstanding Achievement Award from the Indore Management Association
2017
Dilip Shanghvi received Entrepreneur of the Year Award from the All India Management Association (AIMA)
2016
We received DIANA (Distribution Industry Award for Notable Achievements) Award from Healthcare Distribution Alliance, USA
We received Community Care Award from ASSOCHAM (Associated Chambers of Commerce)
Dilip Shanghvi was honoured with Padma Shri (fourth highest civilian award in India) by the Government of India
2015
We received India Pharma Research Development Award 2015 from the Ministry of Chemicals & Fertilizers, Government of India
We received Excellence in CSR Award from UBM-India
Dilip Shanghvi was recognised by NDTV as ‘Business Leader of the Year’
2014
We were listed among the Forbes World 100 Most Innovative Companies
We received Cardiovascular Pharmaceutical Company of the Year Award at the Frost & Sullivan India Healthcare Excellence Awards
Dilip Shanghvi received JRD TATA Corporate Leadership Award from All India Management Association (AIMA)
Dilip Shanghvi received Entrepreneur of the Year Award from Forbes
Dilip Shanghvi received Business Leader of the Year Award from The Economic Times
2013
Sun Pharma was named Company of the Year by The Economic Times
Sun Pharma was named Company of the Year by Business Standard
We were listed among Forbes Asia’s Fab 50 Companies
Uday Baldota received Best CFO in Pharma and Healthcare Award at the CNBC TV-18 CFO Awards
2012
We won NDTV Profit’s Business Leadership of the Year Pharmaceutical Award
Sun Pharma was named Most Outstanding Company of the Year at the CNBC-TV18 India Business Leader Awards
We were listed in Forbes Asia’s Fab 50 Companies
We were listed among Forbes World’s 100 Most Innovative Companies
2011
We were hailed as the Pharmaceutical Company of the Year at the Frost & Sullivan India Healthcare Excellence Awards
Sudhir V. Valia was named Best CFO in Pharma and Healthcare at the CNBC-TV18 CFO Awards
Dilip Shanghvi was recognised as World Entrepreneur of the Year by Ernst & Young
Dilip Shanghvi was recognised as Indian of the Year (Business) by CNN IBN
Dilip Shanghvi was honoured with Businessman of the Year Award by Business India
2010
We received Business Leadership of the Year Award by NDTV PROFIT
Dilip Shanghvi received Entrepreneur of the Year Award by Ernst & Young
2009
We received Rolta Corporate Award – Pharmaceuticals by Dun & Bradstreet
Sudhir V. Valia was named Best CFO in Pharma and Healthcare at the CNBC-TV18 CFO Awards
2008
We won Outstanding Exporter of the Year- Pharmaceuticals, Healthcare and Life Sciences Award at the CNBC TV 18 The International Trade Awards
We received NDTV Profit’s Business Leadership Award
Dilip Shanghvi was named CEO of the Year by Business Standard
Dilip Shanghvi was honoured with Entrepreneur of the Year Award by The Economic Times
2007
Dilip Shanghvi won Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj at the National Quality Award Trust
Dilip Shanghvi was recognised as First Generation Entrepreneur of the Year by CNBC-TV18
2005
Dilip Shanghvi was named Entrepreneur of the Year (Healthcare and Life Science) by Ernst & Young